Roberto Moretto et al., Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. The Oncologist

2017-08-07T11:47:42+02:00